{"id":150860,"date":"2026-10-29T17:16:30","date_gmt":"2026-10-29T16:16:30","guid":{"rendered":"https:\/\/www.we-wealth.com\/?post_type=news&#038;p=150860"},"modified":"2026-10-29T17:16:38","modified_gmt":"2026-10-29T16:16:38","slug":"venture-capital-europe-ai-healthcare-defence","status":"publish","type":"news","link":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence","title":{"rendered":"Demographics, defence drones and the AI bubble: where is venture capital headed at 0100 international Milan?"},"content":{"rendered":"\n<p><br>\u201cStrong Europe\u201d is the theme of the third edition of <strong>0100 International<\/strong>, the private markets conference organised by <strong>Zero One Hundred Conferences<\/strong>. Running until tomorrow at <strong>Palazzo Castiglioni<\/strong>, the headquarters of <strong>Confcommercio Milano<\/strong>, the event brings together around 700 private equity and venture capital decision-makers, with more than 120 speakers from over 50 countries (<strong>We Wealth<\/strong> is among the media partners). The afternoon of the opening day brought three questions into focus that, on closer inspection, boil down to one: where can European venture capital truly make a difference in a world that is ageing, rearming and racing to embrace artificial intelligence?<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/image-3-1024x576.png\" alt=\"Panel di discussione &quot;Can Venture Capital Solve Real-World Problems?&quot; con relatori e moderatore.\" class=\"wp-image-150867\" srcset=\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/image-3-1024x576.png 1024w, https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/image-3-300x169.png 300w, https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/image-3-768x432.png 768w, https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/image-3.png 1280w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"has-text-align-center\"><strong>From left to right: <\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong>Sarah Antor (Helena Capital), Paul Bazin (Daphni), Eric Benhamou (Bgv), Matt Russell (VenCap) and Mads Jensen (Superseed, moderator). Photo by Teresa Scarale.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\"><br><strong>Demographics and Healthcare: betting on assisted reproduction and metabolic health<\/strong><\/h2>\n\n\n\n<p>The first panel, dedicated to healthcare technologies, longevity and biotechnology, opened with a demographic statistic. A fertility rate of at least 2.1 children per woman is needed to maintain a stable population. The rate stands at 1.6 in the United States, 1.3 in Europe, 1.1 in Japan and 0.75 in South Korea. \u201cOne of the biggest existential problems facing Western democracies, which we do not talk about, is depopulation,\u201d said <strong>Aike Ho<\/strong>, general partner at <strong>Acme Capital<\/strong>. A healthcare system without enough doctors and nurses also undermines the social contract: \u201cIf healthcare does not work, a large part of the state does not work.\u201d Ho identified two investment priorities. The first is to make having children easier by applying robotics and computer vision to in vitro fertilisation, reducing costs and increasing success rates. The second is to automate tasks for which demand now exceeds supply, starting with surgery. Looking at the other end of the life cycle is <strong>Christina Ulardic<\/strong>, partner at <strong>Astanor<\/strong>. Since the 1960s, life expectancy has increased by around 20 years, but the ratio between years spent in good health and years spent ill has remained roughly at half: for every additional year of life, half a year is spent with at least one chronic condition. According to Ulardic, the key issue is metabolic health, which is compromised in approximately 90% of US adults and around 60% of Europeans, with research also linking it to cancer and dementia.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The question of scientific sovereignty<\/strong><\/h2>\n\n\n\n<p>Scientific sovereignty is another key issue. According to estimates by <strong>Efpia<\/strong> and <strong>Iqvia<\/strong>, Europe&#8217;s share of commercial clinical trials worldwide fell from 22% in 2013 to 12% in 2023, as studies increasingly shifted towards China and Australia. \u201cThis is not something we should accept,\u201d warned <strong>Alexis Houssou<\/strong>, founding and managing partner at <strong>Hcvc<\/strong>. Where clinical evidence is generated is ultimately where drugs are brought to market. A faster, less expensive system is needed, including through virtual cell models that can be used to test molecules. What about artificial intelligence? Houssou avoids companies that train models on publicly available datasets, which can easily be replicated, and favours those with proprietary data. Ho, meanwhile, points out that many AI-driven drug discovery start-ups founded five to seven years ago found themselves taking on an entirely different business once they had identified a molecule: clinical development, a process that can take 15\u201320 years. In the short to medium term, robotics offers a more attractive proposition by automating tasks that companies already pay for, with exit opportunities compatible with a fund&#8217;s ten-year lifespan. It also offers an unexpected competitive advantage: in the age of AI, \u201crevenue is cheap\u201d and comes and goes, whereas in healthcare, regulation forces every competitor to repeat clinical trials and obtain the necessary authorisations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><br><strong>Dual-Use technologies: the convergence of venture capital and defence<\/strong><\/h2>\n\n\n\n<p>At a panel sponsored by <strong>VenCap<\/strong> and moderated by <strong>Mads Jensen<\/strong>, co-founder of <strong>Superseed<\/strong>, the question was whether venture capital can solve real-world problems. <strong>Paul Bazin<\/strong>, partner at Paris-based <strong>Daphni<\/strong>, explained that the fund assesses every investment against the UN Sustainable Development Goals. For now, defence remains outside its investment thesis, while energy\u2014which is also a matter of sovereignty\u2014has long been part of it. <strong>Eric Benhamou<\/strong>, founder and general partner at <strong>Bgv<\/strong>, based in Menlo Park, takes the opposite view: \u201cOur mandate is to maximise returns for our investors.\u201d Growing defence budgets, he argued, are not a short-term phenomenon. This has led to the creation of a dedicated dual-use unit based in Israel, which adapts military research for civilian applications.<\/p>\n\n\n\n<p>One example is reinforced drones capable of carrying up to 50 kilograms of sensors to inspect refineries and power plants, replacing human inspection teams. For <strong>Sarah Antor<\/strong>, managing partner at <strong>Helena Capital<\/strong>, the product often remains the same; only the label changes. A Munich-based company originally established to serve ports, operating in environments where satellite signals are disrupted, has received enquiries from the French, German and US defence ministries. An exoskeleton designed for surgeons has become part of <strong>Nato&#8217;s Diana programme<\/strong>. Even a video game company has been approached by the <strong>Pentagon<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><br><strong>Waste in the era of zero interest rates<\/strong><\/h2>\n\n\n\n<p><strong>Matt Russell<\/strong>, investment director at <strong>VenCap<\/strong>, brought the discussion back to the numbers. VenCap is a fund-of-funds that has been investing in venture capital funds for around 40 years and has selected approximately 500 of them. Its data show that the top 1% of exits account for roughly half of the capital returned by the entire industry. Repeating the calculation for the past eight years pushes that share to 55%. This concentration explains the fund&#8217;s focus on the strongest generalist managers. Impact, Russell added, often comes from unexpected places. Consider the air miles saved through the use of a videoconferencing platform such as <strong>Zoom<\/strong>. More capital is not enough, Benhamou warned. During the years of zero interest rates, money was abundant and, as an industry, \u201cwe wasted most of it\u201d. Quality entrepreneurs are in short supply.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><br><strong>\u00a0Cost arbitrage: Europe&#8217;s advantage in engineering and talent<\/strong><\/h2>\n\n\n\n<p>The question of scale remains, often prompting European founders to move to the United States. Antor, an American who has lived in Europe for 20 years, sees an opportunity for arbitrage instead: undervalued European technologies and an industrial base, particularly German engineering, that is lacking across the Atlantic. With offices in Munich and New York, the fund invests approximately 30% of its capital in US companies. It also seeks to connect start-ups with major industrial and defence groups that could become both customers and acquirers. Benhamou sees the arbitrage opportunity in talent. For equivalent skills, an AI specialist with a PhD costs six times as much in Silicon Valley as in Bangalore and approximately twice as much as in Western Europe. Its impact can be summed up in one line: \u201cProduce more while consuming less.\u201d In parallel, a panel on artificial intelligence, moderated by <strong>Geri Kirilova<\/strong>, partner at <strong>Laconia<\/strong>, opened with a figure highlighted at the start of the conference: AI now absorbs almost two-thirds of global venture capital. Among the speakers, <strong>Briehan Burke<\/strong>, general partner at <strong>Keen Venture Partners<\/strong>, is betting on software that replaces services. Small and medium-sized enterprises spend little on software licences but substantial amounts on lawyers and consultants. AI can therefore sell the completed work rather than the tool used to produce it. <strong>Pedro Santos Vieira<\/strong>, partner at <strong>500 Global<\/strong>, takes a similar approach, seeking teams capable of owning an entire workflow. One portfolio company operating in the relatively unglamorous debt collection business has <strong>replaced its entire workforce in Peru with an AI agent<\/strong>. <strong>Daniel Minchin<\/strong>, investment director at <strong>OurCrowd<\/strong>, takes a more cautious view of inflated late-stage funding rounds. He prefers traditional companies, from cybersecurity to industrial companies, that use AI to improve their margins.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><br><strong>Where AI capital is concentrated and the risk of a bubble<\/strong><\/h2>\n\n\n\n<p><strong>Jose Marin<\/strong>, co-founder of <strong>FJ Labs<\/strong>, distinguishes between three categories of companies: those valued on promises rather than revenue; those growing at unprecedented rates but with uncertain margins; and those combining rapid growth with solid margins. In his view, only the last category will endure. The cracks could begin to appear when the revenue expected by major model developers materialises later than anticipated, leaving excess capacity and driving prices down. As for Europe, Marin, who identifies as Southern European, points to a cultural barrier even before regulatory constraints come into play. In countries such as Spain and Italy, failure can carry consequences for years, while the social stigma remains enormous.<\/p>\n\n\n\n<p>&#8220;How can we accept failure the way it happens in the United States?\u201d he asked.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At the first day of 0100 International in Milan, funds of funds, asset managers and investors discussed longevity, dual-use technologies and artificial intelligence, from declining birth rates and the concentration of returns to fears of a bubble. VenCap, FJ Labs, 500 Global and OurCrowd were among the key players.<\/p>\n","protected":false},"author":88501,"featured_media":150866,"template":"","categories":[3779,3780],"tags":[4570,4087,4569,3782,3768],"collana-video":[],"class_list":["post-150860","news","type-news","status-publish","has-post-thumbnail","hentry","category-private-market-istituzionali","category-venture-capital","tag-0100-international","tag-ai","tag-ai-investment","tag-private-markets","tag-venture-capital"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Venture Capital in Europe: AI, Healthcare and Defence | We Wealth<\/title>\n<meta name=\"description\" content=\"At 0100 International Milan, investors discuss European venture capital, AI, healthcare, dual-use defence technologies and the risk of an AI bubble\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Venture Capital in Europe: AI, Healthcare and Defence | We Wealth\" \/>\n<meta property=\"og:description\" content=\"At 0100 International Milan, investors discuss European venture capital, AI, healthcare, dual-use defence technologies and the risk of an AI bubble\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence\" \/>\n<meta property=\"og:site_name\" content=\"We Wealth\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/wewealthsocial\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-29T16:16:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@we__wealth\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence\"},\"author\":{\"name\":\"Annalisa Lazzari\",\"@id\":\"https:\/\/www.we-wealth.com\/#\/schema\/person\/1ca67ac74cd846539d046fea921a3ca8\"},\"headline\":\"Demographics, defence drones and the AI bubble: where is venture capital headed at 0100 international Milan?\",\"datePublished\":\"2026-10-29T16:16:30+00:00\",\"dateModified\":\"2026-10-29T16:16:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence\"},\"wordCount\":1394,\"publisher\":{\"@id\":\"https:\/\/www.we-wealth.com\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp\",\"width\":1200,\"height\":675},\"thumbnailUrl\":\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp\",\"keywords\":[\"0100 International\",\"AI\",\"AI Investment\",\"private markets\",\"venture capital\"],\"articleSection\":[\"Private Market and Institutional\",\"Venture Capital\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.we-wealth.com\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence\",\"url\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence\",\"name\":\"Venture Capital in Europe: AI, Healthcare and Defence | We Wealth\",\"isPartOf\":{\"@id\":\"https:\/\/www.we-wealth.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp\",\"datePublished\":\"2026-10-29T16:16:30+00:00\",\"dateModified\":\"2026-10-29T16:16:38+00:00\",\"description\":\"At 0100 International Milan, investors discuss European venture capital, AI, healthcare, dual-use defence technologies and the risk of an AI bubble\",\"breadcrumb\":{\"@id\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#primaryimage\",\"url\":\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp\",\"contentUrl\":\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp\",\"width\":1280,\"height\":720,\"caption\":\"Uomini in abito osservano una mappa olografica dell'Europa con connessioni luminose.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.we-wealth.com\/en\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Venture Capital\",\"item\":\"https:\/\/www.we-wealth.com\/en\/category\/venture-capital\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Demographics, defence drones and the AI bubble: where is venture capital headed at 0100 international Milan?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.we-wealth.com\/#website\",\"url\":\"https:\/\/www.we-wealth.com\/\",\"name\":\"We Wealth\",\"description\":\"We Wealth | News, Insights and Articles for Those Interested in Investing in Italy\",\"publisher\":{\"@id\":\"https:\/\/www.we-wealth.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.we-wealth.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"NewsMediaOrganization\",\"@id\":\"https:\/\/www.we-wealth.com\/#organization\",\"name\":\"We Wealth\",\"url\":\"https:\/\/www.we-wealth.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.we-wealth.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2025\/01\/Nuovo-logo.png\",\"contentUrl\":\"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2025\/01\/Nuovo-logo.png\",\"width\":970,\"height\":970,\"caption\":\"We Wealth\"},\"image\":{\"@id\":\"https:\/\/www.we-wealth.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/wewealthsocial\",\"https:\/\/x.com\/we__wealth\",\"https:\/\/www.linkedin.com\/company\/wewealth\/mycompany\/\",\"https:\/\/www.youtube.com\/@wewealth90\/\",\"https:\/\/www.instagram.com\/wewealth_next\/\"],\"publishingPrinciples\":\"https:\/\/www.we-wealth.com\/codice-editoriale\",\"ownershipFundingInfo\":\"https:\/\/www.we-wealth.com\/chi-siamo\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.we-wealth.com\/#\/schema\/person\/1ca67ac74cd846539d046fea921a3ca8\",\"name\":\"Annalisa Lazzari\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Venture Capital in Europe: AI, Healthcare and Defence | We Wealth","description":"At 0100 International Milan, investors discuss European venture capital, AI, healthcare, dual-use defence technologies and the risk of an AI bubble","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence","og_locale":"en_US","og_type":"article","og_title":"Venture Capital in Europe: AI, Healthcare and Defence | We Wealth","og_description":"At 0100 International Milan, investors discuss European venture capital, AI, healthcare, dual-use defence technologies and the risk of an AI bubble","og_url":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence","og_site_name":"We Wealth","article_publisher":"https:\/\/www.facebook.com\/wewealthsocial","article_modified_time":"2026-10-29T16:16:38+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_site":"@we__wealth","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#article","isPartOf":{"@id":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence"},"author":{"name":"Annalisa Lazzari","@id":"https:\/\/www.we-wealth.com\/#\/schema\/person\/1ca67ac74cd846539d046fea921a3ca8"},"headline":"Demographics, defence drones and the AI bubble: where is venture capital headed at 0100 international Milan?","datePublished":"2026-10-29T16:16:30+00:00","dateModified":"2026-10-29T16:16:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence"},"wordCount":1394,"publisher":{"@id":"https:\/\/www.we-wealth.com\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp","width":1200,"height":675},"thumbnailUrl":"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp","keywords":["0100 International","AI","AI Investment","private markets","venture capital"],"articleSection":["Private Market and Institutional","Venture Capital"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.we-wealth.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence","url":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence","name":"Venture Capital in Europe: AI, Healthcare and Defence | We Wealth","isPartOf":{"@id":"https:\/\/www.we-wealth.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#primaryimage"},"image":{"@id":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#primaryimage"},"thumbnailUrl":"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp","datePublished":"2026-10-29T16:16:30+00:00","dateModified":"2026-10-29T16:16:38+00:00","description":"At 0100 International Milan, investors discuss European venture capital, AI, healthcare, dual-use defence technologies and the risk of an AI bubble","breadcrumb":{"@id":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#primaryimage","url":"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp","contentUrl":"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2026\/10\/cover_vc_0100_1280x720-1.webp","width":1280,"height":720,"caption":"Uomini in abito osservano una mappa olografica dell'Europa con connessioni luminose."},{"@type":"BreadcrumbList","@id":"https:\/\/www.we-wealth.com\/en\/news\/venture-capital-europe-ai-healthcare-defence#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.we-wealth.com\/en"},{"@type":"ListItem","position":2,"name":"Venture Capital","item":"https:\/\/www.we-wealth.com\/en\/category\/venture-capital"},{"@type":"ListItem","position":3,"name":"Demographics, defence drones and the AI bubble: where is venture capital headed at 0100 international Milan?"}]},{"@type":"WebSite","@id":"https:\/\/www.we-wealth.com\/#website","url":"https:\/\/www.we-wealth.com\/","name":"We Wealth","description":"We Wealth | News, Insights and Articles for Those Interested in Investing in Italy","publisher":{"@id":"https:\/\/www.we-wealth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.we-wealth.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"NewsMediaOrganization","@id":"https:\/\/www.we-wealth.com\/#organization","name":"We Wealth","url":"https:\/\/www.we-wealth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.we-wealth.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2025\/01\/Nuovo-logo.png","contentUrl":"https:\/\/www.we-wealth.com\/wp-content\/uploads\/2025\/01\/Nuovo-logo.png","width":970,"height":970,"caption":"We Wealth"},"image":{"@id":"https:\/\/www.we-wealth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/wewealthsocial","https:\/\/x.com\/we__wealth","https:\/\/www.linkedin.com\/company\/wewealth\/mycompany\/","https:\/\/www.youtube.com\/@wewealth90\/","https:\/\/www.instagram.com\/wewealth_next\/"],"publishingPrinciples":"https:\/\/www.we-wealth.com\/codice-editoriale","ownershipFundingInfo":"https:\/\/www.we-wealth.com\/chi-siamo"},{"@type":"Person","@id":"https:\/\/www.we-wealth.com\/#\/schema\/person\/1ca67ac74cd846539d046fea921a3ca8","name":"Annalisa Lazzari"}]}},"_links":{"self":[{"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/news\/150860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/users\/88501"}],"version-history":[{"count":2,"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/news\/150860\/revisions"}],"predecessor-version":[{"id":150876,"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/news\/150860\/revisions\/150876"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/media\/150866"}],"wp:attachment":[{"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/media?parent=150860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/categories?post=150860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/tags?post=150860"},{"taxonomy":"collana-video","embeddable":true,"href":"https:\/\/www.we-wealth.com\/en\/wp-json\/wp\/v2\/collana-video?post=150860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}